montanide + sargramostim

Montanide + sargramostim is a combination of two pharmaceuticals commonly used as adjuvants in cancer vaccine protocols, particularly peptide-based vaccines targeting tumor-associated antigens, such as survivin. **Montanide ISA 51** is an immunologic adjuvant—a water-in-oil emulsion—known for enhancing antigen-specific immune responses by promoting depot formation and sustained antigen release. **Sargramostim** is recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates differentiation and proliferation of dendritic cells and improves antigen presentation. When used together, Montanide is typically co-administered with the vaccine to boost immune activation, while sargramostim is given subcutaneously near the injection site to further stimulate the local immune response and facilitate vaccine efficacy. This combination is most frequently employed in phase I and II clinical trials as part of investigational therapies for various cancers, such as glioblastoma, breast cancer, ovarian cancer, and multiple myeloma, generally as adjuncts to peptide vaccines (e.g., SurVaxM, galinpepimut-S, WT1 peptide vaccine)[1][2][3][5][6]. **Mechanism of action:** - Montanide enhances immunogenicity by improving antigen uptake and recognition by antigen-presenting cells. - Sargramostim stimulates dendritic cells and other immune effectors, promoting a robust adaptive immune response.

Brand names

montanide + sargramostim

Other names

montanide ISA 51 + sargramostim